ReviewBritish journal of pharmacology2022
Novel drug developmental strategies for treatment-resistant depression.
Review in British journal of pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 7 syntheses or guidelines pooled it, 100 citations in OpenAlex.
- Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects.European archives of psychiatry and clinical neuroscience · 2026Pooled it
- Potential Role of Botulinum Neurotoxin Type A as a Supportive Intervention for Depressive Symptoms: A Systematic Review.Aesthetic plastic surgery · 2026Pooled it
- Efficacy and safety of esketamine on major depression, postpartum depression and perioperative depression: a systematic review and meta-analysis.Molecular psychiatry · 2026Pooled it
- Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses.Molecular psychiatry · 2025Pooled it
- The Relationship between Post-Traumatic Stress Disorder Due to Brain Injury and Glutamate Intake: A Systematic Review.Nutrients · 2024Pooled it
- A systematic review and meta-analysis of the efficacy of ketamine and esketamine on suicidal ideation in treatment-resistant depression.European journal of clinical pharmacology · 2024Pooled it
- Efficacy and tolerability of minocycline in depressive patients with or without treatment-resistant: a meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2023Pooled it
- Ferroptosis in depression: mechanisms, association, and therapeutic strategies.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Samidorphan sadness: does the addition of samidorphan to olanzapine have prodepressive effects?International clinical psychopharmacology · 2026Article
- Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression.Molecular psychiatry · 2026Article
- Glutamatergic Mechanisms Underlying the Antidepressant-Like Effects of 1-(Phenylselanyl)-2-(p-tolyl)indolizine in Mice.Psychopharmacology · 2026Article
- [Psychiatry as clinical neuroscience].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- The HPA axis and kynurenine pathway: exploring the role of stress and neuroinflammation in treatment-resistant depression.Pharmacological reports : PR · 2026Review
- Exploring New Frontiers in Pharmacological Treatment of Depression: A Review on Recent Advances.Current medicinal chemistry · 2026Review
- A U-shaped association between sleep duration and depression in adult prescription opioid users.Frontiers in psychiatry · 2026Article
- Article
- Quercetin as a Novel Antidepressant: Mechanistic Insights into Its Neuroprotective and Anti-inflammatory Effects.Molecular neurobiology · 2025Article
- Knockdown of USP22 alleviates LPS-induced microglial inflammation and mouse depressive-like behaviors via KAT2A.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Study on subtyping and Traditional Chinese Medicine treatment of depression based on machine learning and text mining.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2025Article
- [Translational psychiatry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment-resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational animal models and (3) objective diagnostic biomarkers. Here, we review novel drug targets and drug candidates currently investigated in Phase I-III clinical trials. The most promising approaches are inhibition of glutamatergic neurotransmission by NMDA and mGlu
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.